Work

Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.6033

Authors: Julie E. Bauman, Umamaheswar Duvvuri, William E. Gooding, Neil D. Gross, John Song, Wendell Gray Yarbrough, Faye M. Johnson, Lin Wang, Antonio Jimeno, Malabika Sen, Jason I Kass, Jonas Talmadge Johnson, Robert L. Ferris, Seungwon Kim, Tanya J Rath, Fred R. Hirsch, Gordon B. Mills, Natanya I Pollock, John T Flaherty, Jennifer R. Grandis

Institutions: UPMC Hillman Cancer Center, University of Pittsburgh, Oregon Health & Science University, University of Colorado Denver, Yale Cancer Center, The University of Texas MD Anderson Cancer Center, University of Colorado Cancer Center, Swarthmore College

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2761128124

Cites:

Cited by: 5

Related to: 10